Gilead Sciences, Inc. , with a market cap of $68.16B, is a research-based biopharmaceutical company, which develops and markets therapies to treat life-threatening infectious diseases with the core portfolio focused on HIV, liver diseases, such as hepatitis B and C, and cardiovascular/metabolic and respiratory conditions.
http://seekingalpha.com/article/1302001-gilead-sciences-stribild-recommended-great-long-term-hold?source=feed
http://seekingalpha.com/article/1302001-gilead-sciences-stribild-recommended-great-long-term-hold?source=feed
No comments:
Post a Comment